AGIOS PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $54.0M | $36.5M | $26.8M | $14.2M | $0 | $0 | $117.9M | $94.4M |
| Cost of Revenue | $6.3M | $4.2M | $2.9M | $1.7M | $0 | $0 | $1.3M | $1.4M |
| Gross Profit | $47.7M | $32.3M | $23.9M | $12.5M | $0 | $0 | $116.6M | $93.0M |
| Gross Margin | 88.3% | 88.6% | 89.3% | 88.0% | — | — | 98.9% | 98.5% |
| Operating Expenses | ||||||||
| Research & Development | $339.5M | $301.3M | $295.5M | $279.9M | $257.0M | $220.8M | $214.3M | $341.3M |
| SG&A Expense | $180.3M | $156.8M | $119.9M | $121.7M | $121.4M | $115.1M | $102.0M | $114.1M |
| Operating Income | $-472.1M | $-425.7M | $-391.5M | $-389.0M | $-378.4M | $-335.9M | $-316.3M | $-362.5M |
| Operating Margin | -873.9% | -1,166.5% | -1,459.5% | -2,732.1% | — | — | -268.2% | -384.0% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-413.8M | $718.0M | $-352.1M | $-231.8M | $-356.5M | $-329.3M | $-301.4M | $-346.0M |
| Income Tax Expense | $-1.0M | $44.2M | $0 | $0 | — | — | $0 | $0 |
| Net Income | $-412.8M | $673.7M | $-352.1M | $-231.8M | $1.60B | $-327.4M | $-411.5M | $-346.0M |
| Net Margin | -764.0% | 1,845.9% | -1,312.6% | -1,627.8% | — | — | -349.0% | -366.6% |
| EPS (Basic) | $-7.12 | $11.86 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | $-6.03 |
| EPS (Diluted) | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | $-6.03 |
| Shares Outstanding (Basic) | 58.0M | 56.8M | 55.7M | 54.8M | 60.4M | 69.0M | 60.0M | 58.2M |
| Shares Outstanding (Diluted) | 58.0M | 57.9M | 55.7M | 54.8M | 60.4M | 69.0M | 60.0M | 58.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |